Vertex Pharmaceuticals Inc

2026. g. 4. sept. 23:30 UTC

Vertex Pharmaceuticals shares are higher in after-market trading, despite declining from an initial peak. No specific news was identified to explain the movement.

2026. g. 2. sept. 19:56 UTC

Morgan Stanley reinstated its Overweight rating on Vertex Pharmaceuticals, setting a price target of $665 following the acquisition of Crinetics Pharmaceuticals.

2026. g. 1. sept. 20:08 UTC

Vertex Pharmaceuticals is rising following its $10 billion acquisition of Crinetics Pharmaceuticals, which aims to enhance its innovation pipeline and revenue growth.

2026. g. 31. aug. 20:07 UTC

Vertex Pharmaceuticals shares are higher, reflecting broader market gains amid inflation concerns and potential monetary tightening discussed at the Jackson Hole Symposium.

2026. g. 27. aug. 20:07 UTC

Vertex Pharmaceuticals shares are roughly flat as market performance remains stable. Initial jobless claims declined, indicating resilience in the labor market.

2026. g. 26. aug. 23:06 UTC

Vertex Pharmaceuticals shares are trading lower in after-market hours. No specific news was identified to explain the price movement.

2026. g. 24. aug. 19:16 UTC

Vertex Pharmaceuticals shares are little changed amid minor fluctuations. Market participants await upcoming events, including a speech by Federal Reserve Chair Kevin Warsh.

2026. g. 21. aug. 19:26 UTC

Vertex Pharmaceuticals is trading higher, reflecting a broader rebound in U.S. stocks amid increased market sentiment and notable volatility during the session.

2026. g. 20. aug. 20:02 UTC

Vertex Pharmaceuticals shares are lower today, reflecting broader market pressures after Walmart's disappointing sales report raised concerns about consumer spending.

2026. g. 19. aug. 23:46 UTC

Vertex Pharmaceuticals shares are trading roughly flat in after-market hours. The stock remains above its 20-day moving average and has finished higher for four consecutive sessions.

2026. g. 18. aug. 20:03 UTC

Vertex Pharmaceuticals shares are higher today, continuing a notable upward trend since Monday. No specific company news was identified to explain the advance.

2026. g. 17. aug. 23:36 UTC

Vertex Pharmaceuticals shares are trading higher in after-market hours. No specific news was identified to explain this movement amid a lower broader market.

2026. g. 14. aug. 20:02 UTC

Vertex Pharmaceuticals is lower today, marking four straight days of declines. Broader market sentiment may be affected by a drop in U.S. retail sales.

2026. g. 13. aug. 23:26 UTC

Vertex Pharmaceuticals shares are higher in after-market hours, following a modest decline earlier. The stock remains above its 20-day moving average.

2026. g. 12. aug. 19:42 UTC

Vertex Pharmaceuticals is trading lower today, pulling back from an earlier session high. No specific news has been identified to explain the decline.

2026. g. 11. aug. 19:36 UTC

Vertex Pharmaceuticals gained today after Bank of America Merrill Lynch added it to the US 1 List, reflecting strong confidence in its future prospects.

2026. g. 10. aug. 20:02 UTC

Vertex Pharmaceuticals shares rose following Sionna Therapeutics' trial failure, easing competitive pressure on Trikafta. BMO analyst noted this as a positive for Vertex's franchise.

2026. g. 7. aug. 19:51 UTC

Vertex Pharmaceuticals shares are higher as the Biotechnology sector strengthens. The company reported $3.33 billion in second-quarter revenue, driven by cystic fibrosis sales.

2026. g. 6. aug. 19:26 UTC

Vertex Pharmaceuticals is trading near unchanged levels with no specific news identified. The stock remains within a narrow range today.

2026. g. 5. aug. 19:16 UTC

Vertex Pharmaceuticals shares are higher as Barclays raises its price target to $617. Truist maintains a Buy rating and sets a target of $565.

2026. g. 4. aug. 20:05 UTC

Vertex Pharmaceuticals is rising today, buoyed by analyst upgrades and a strong Q2 revenue of $3.33 billion, with TD Cowen raising its target to $550.

2026. g. 3. aug. 23:26 UTC

Vertex Pharmaceuticals reported second-quarter revenue of $3.33 billion, exceeding estimates. The company raised its full-year guidance to between $13.1 billion and $13.2 billion.

2026. g. 31. jūl. 19:56 UTC

Vertex Pharmaceuticals is trading lower amid broader market trends, despite its $10 billion acquisition of Crinetics Pharmaceuticals still pending closure.

2026. g. 30. jūl. 23:26 UTC

Vertex Pharmaceuticals shares are lower in after-market hours, following a notable dip earlier in the session. No specific news was identified to explain the decline.

2026. g. 29. jūl. 23:36 UTC

Vertex Pharmaceuticals Inc shares are higher in after-market trading, recovering from an earlier dip. The stock shows notable volatility within its recent trading range.

2026. g. 28. jūl. 15:22 UTC

Vertex Pharmaceuticals Inc. shares are higher as biotechnology stocks advance. This follows a recent trend of higher daily closes since Monday's close.

2026. g. 27. jūl. 19:51 UTC

Vertex Pharmaceuticals is gaining modestly today amid broader market volatility and a significant decline in crude oil prices affecting overall sentiment.

2026. g. 24. jūl. 13:46 UTC

Vertex Pharmaceuticals is experiencing modest gains amid broader market sentiment influenced by a drop in initial jobless claims to a near 54-year low.

2026. g. 22. jūl. 20:06 UTC

Vertex Pharmaceuticals is lower amid market volatility and uncertainty ahead of the Federal Reserve meeting, reflecting a cumulative decline since Tuesday's close.

2026. g. 20. jūl. 18:41 UTC

Vertex Pharmaceuticals shares are lower amid a broader decline in the Biotechnology sector. The company recently completed a $10 billion acquisition to enhance its portfolio.